Immunologic effects of continuous-flow left ventricular assist devices before and after heart transplant

Journal of Heart and Lung Transplantation

Volumn 35, Issue 8, 2016, Pages 1024-1030

  Ko, Byung Soo ^a,d   Drakos, Stavros ^a,b,d   Kfoury, Abdallah G ^c,d   Hurst, Denise ^a   Stoddard, Gregory J ^e   Willis, Carrie A ^c,d   Delgado, Julio C ^a   Hammond, Elizabeth H ^a,c   Gilbert, Edward M ^a,b,d   Alharethi, Rami ^c,d   Revelo, Monica P ^a   Nativi Nicolau, Jose ^a,b,d   Reid, Bruce B ^c   McKellar, Stephen H ^a   Wever Pinzon, Omar ^a,b,d   Miller, Dylan V ^c   Eckels, David D ^a   Fang, James C ^a,b,d   Selzman, Craig H ^a   Stehlik, Josef ^a,b,d  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c INTERMOUNTAIN MEDICAL CENTER   (United States)

^d Utah Transplantation Affiliated Hospitals (UTAH) Cardiac Transplant Program   (United States)

^e UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

acute cellular rejection; allosensitization; antibody mediated rejection; continuous flow left ventricular assist device; transplant outcome

Indexed keywords

ACUTE GRAFT REJECTION; ADULT; ANTIBODY DETECTION; ANTIBODY MEDIATED REJECTION; ARTICLE; AUTOIMMUNITY; CARDIOVASCULAR PARAMETERS; COHORT ANALYSIS; CONTINUOUS FLOW LEFT VENTRICULAR ASSIST DEVICE; CONTROLLED STUDY; CROSS REACTION; FEMALE; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMAN; HUMAN CELL; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TIME TO TREATMENT; TREATMENT DURATION; GRAFT REJECTION; HEART ASSIST DEVICE; HEART FAILURE; MIDDLE AGED;

ALLOANTIBODY;

FEMALE; GRAFT REJECTION; HEART FAILURE; HEART TRANSPLANTATION; HEART-ASSIST DEVICES; HUMANS; ISOANTIBODIES; MALE; MIDDLE AGED;

EID: 84991669645     PISSN: 10532498     EISSN: 15573117     Source Type: Journal    
DOI: 10.1016/j.healun.2016.05.001     Document Type: Article

References (24)

1. 1 Lund, L.H., Edwards, L.B., Kucheryavaya, A.Y., et al. The Registry of the International Society for Heart and Lung Transplantation: thirty-second official adult heart transplant report—. J Heart Lung Transplant 201:34 (2015), 1244–1254.
2. 2 Askar, M., Hsich, E., Reville, P., et al. HLA and MICA allosensitization patterns among patients supported by ventricular assist devices. J Heart Lung Transplant 32 (2013), 1241–1248.
3. 3 Joyce, D.L., Southard, R.E., Torre-Amione, G., Noon, G.P., Land, G.A., Loebe, M., Impact of left ventricular assist device (LVAD)-mediated humoral sensitization on post-transplant outcomes. J Heart Lung Transplant 24 (2005), 2054–2059.
4. 4 Pamboukian, S.V., Costanzo, M.R., Dunlap, S., et al. Relationship between bridging with ventricular assist device on rejection after heart transplantation. J Heart Lung Transplant 24 (2005), 310–315.
5. 5 John, R., Pagani, F.D., Naka, Y., et al. Post-cardiac transplant survival after support with a continuous-flow left ventricular assist device: impact of duration of left ventricular assist device support and other variables. J Thorac Cardiovasc Surg 140 (2010), 174–181.
6. 6 Organ Procurement and Transplantation Network. Allocation calculators. Available at: http://optn.transplant.hrsa.gov/converge/resources/allocationcalculators.asp.
7. 7 Stewart, S., Winters, G.L., Fishbein, M.C., et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 24 (2005), 1710–1720.
8. 8 Berry, G.J., Burke, M.M., Andersen, C., et al. The 2013 International Society for Heart and Lung Transplantation working formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation. J Heart Lung Transplant 32 (2013), 1147–1162.
9. 9 Kfoury, A., Stehlik, J., Renlund, D.G., et al. Impact of repetitive episodes of antibody-mediated or cellular rejection on cardiovascular mortality in cardiac transplant recipients: defining rejection patterns. J Heart Lung Transplant 25 (2006), 1277–1282.
10. 10 John, R., Lietz, K., Schuster, M., et al. Immunologic sensitization in recipients of left ventricular assist devices. J Thorac Cardiovasc Surg 125 (2003), 578–591.
11. 11 Gonzalez-Stawinski, G.V., Cook, D.J., Chang, A.S., et al. Ventricular assist devices and aggressive immunosuppression: looking beyond overall survival. J Heart Lung Transplant 25 (2006), 613–618.
12. 12 Drakos, S.G., Stringham, J.C., Long, J.W., et al. Prevalence and risks of allosensitization in HeartMate left ventricular assist device recipients: the impact of leukofiltered cellular blood product transfusions. J Heart Lung Transplant 133 (2007), 1612–1619.
13. 13 Kidambi, S., Mohamedali, B., Bhat, G., Clinical outcomes in sensitized heart transplant patients bridged with ventricular assist devices. Clin Transplant 29 (2015), 499–505.
14. 14 George, I., Colley, P., Russo, M.J., et al. Association of device surface and biomaterials with immunologic sensitization after mechanical support. J Thorac Cardiovasc Surg 135 (2008), 1372–1379.
15. 15 Alba, A., Tinckam, K., Foroutan, F., et al. Factors associated with anti-human leukocyte antigen antibodies in patients supported with continuous-flow devices and effect on probability of transplant and post-transplant outcomes. J Heart Lung Transplant 34 (2015), 685–692.
16. 16 Pagani, F.D., Dyke, D.B., Wright, S., Cody, R., Aaronson, K.D., Development of anti-major histocompatibility complex class I or II antibodies following left ventricular assist device implantation: effects on subsequent allograft rejection and survival. J Heart Lung Transplant 20 (2001), 646–653.
17. 17 Arnaoutakis, G.J., George, T.J., Kilic, A., et al. Effect of sensitization in US heat transplant recipients bridged with a ventricular assist device: update in a modern cohort. J Thorac Cardiovasc Surg 142 (2011), 1236–1245.
18. 18 Betkowski, A.S., Graff, R., Chen, J.J., Hauptman, P.J., Panel-reactive antibody screening practices prior to heart transplantation. J Heart Lung Transplant 21 (2002), 644–650.
19. 19 Schaffer, J.M., Singh, S.K., Reitz, B.A., Oyer, P.E., Robbins, R.C., Mallidi, H.R., Heart transplant graft survival is improved after a reduction in panel reactive antibody activity. J Thorac Cardiovasc Surg 145 (2013), 555–565.
20. 20 Stehlik, J., Islam, N., Hurst, D., et al. Utility of virtual crossmatch in sensitized patients awaiting heart transplant. J Heart Lung Transplant 28 (2009), 1129–1134.
21. 21 Wever-Pinzon, O., Drakos, S.G., Kfoury, A.G., et al. Morbidity and mortality in heart transplant candidates supported with mechanical circulatory support. Is reappraisal of the current UNOS thoracic organ allocation policy justified?. Circulation 127 (2013), 452–462.
22. 22 Lund, L.H., Edwards, L.B., Kucheryavaya, A.Y., et al. The registry of International Society for Heart and Lung Transplantation: thirtieth official adult heart transplant report—2013; focus theme: age. J Heart Lung Transplant 32 (2013), 951–964.
23. 23 Roddy, M., Clemente, M., Poggio, E.D., et al. Heterogeneous alterations in human alloimmunity associated with immunization. Transplantation 80 (2005), 297–302.
24. 24 Wallace, W.D., Weigt, S.S., Farver, C.F., Update on pathology of antibody-mediated rejection in the lung allograft. Curr Opin Organ Transplant 19 (2014), 303–308.